Kaposi sarcoma in a fingolimod-treated patient with multiple sclerosis. (September 2016)

• Record Type: Journal Article
• Authors: Walker, Susan; Brew, Bruce
• Is Part Of: Journal of clinical neuroscience. Volume 31(2016:Sep.)
• Page Start: 217
• Page End: 218
• Publication Date: 2016-09
• Subjects: Adverse effect -- Fingolimod -- Kaposi sarcoma -- Malignancy -- Multiple sclerosis; Brain -- Surgery -- Periodicals; Neurosciences -- Periodicals; Nervous system -- Surgery -- Periodicals; Brain -- surgery -- Periodicals; Neurosurgical Procedures -- Periodicals; Neurosciences -- Periodicals; Electronic journals; 616.8
• DOI: 10.1016/j.jocn.2016.03.001
• Languages: English
• ISSNs: 0967-5868

Abstract

Highlights: Fingolimod is a disease-modifying therapy used in the treatment of relapsing-remitting multiple sclerosis. This is the second reported case of Kaposi sarcoma occurring in a patient treated with fingolimod. Certain infections and malignancies may be increased in patients taking fingolimod. We are learning more about fingolimod therapy and its association with infections and malignancies with time. Abstract: Kaposi sarcoma (KS) is a vascular tumour of endothelial cell origin, associated with human herpes virus 8. It develops in one of four clinical settings, one of which is iatrogenic immunosuppression. We present the case of a 46 year-old man with relapsing-remitting multiple sclerosis who developed KS in the context of fingolimod use. To our knowledge, this is the second reported case of KS in a fingolimod-treated individual. This case highlights potential risks associated with immunosuppression with this medicine and ongoing need for vigilance in assessing for such complications.